

Halo Biosciences Announces Publication of Positive Phase 1 Data in the Journal of Clinical Investigation

- Phase 1 study confirms activity against a novel respiratory target -

- Phase 2 clinical study initiated in patients with pulmonary hypertension -

Palo Alto, May 5, 2022 - Halo Biosciences, a biotechnology company focused on creating first-in-class, disease-modifying therapies that edit the extracellular matrix, announced today the publication of positive Phase 1 data in the Journal of Clinical Investigation. The results establish the potential of Halo's approach to applying new extracellular matrix (ECM) mechanisms for the treatment of pulmonary hypertension and fibrotic diseases. Based on these results, a Phase 2 clinical study of hymecromone has been initiated in patients with pulmonary hypertension.

"The data from our Phase 1 clinical study are very encouraging and we believe they support our approach to targeting hyaluronan to treat many diseases of the lung, and we look forward to reporting the results from our Phase 2 study in pulmonary hypertension patients," said Dr. Paul Bollyky, lead author on the paper and Associate Professor of Medicine, Microbiology and Immunology at Stanford University and co-founder and CSO of Halo Biosciences. "We believe our approach opens up a new class of therapeutic molecules that is able to target a novel component of multiple inflammatory and fibrotic diseases."

"Higher levels of hyaluronan are known to be associated with the progression of many inflammatory and fibrotic diseases, including pulmonary hypertension, cystic fibrosis, COVID-19, and others. Targeting hyaluronan represents a potential novel, disease-modifying treatment approach," said Dr. Roham Zamanian, Associate Professor of Medicine at Stanford University and a leading global expert in the treatment of pulmonary hypertension. "These data, coupled with extensive preclinical data on hymecromone, provide a compelling case for the application of hymecromone to treat certain groups of pulmonary hypertension patients."

Dr. Zamanian is the lead investigator for the Phase IIa trial of hymecromone that is currently enrolling patients with Group 1 and Group 3 pulmonary hypertension. The study builds on preclinical work of Halo collaborator Harry Karmouty-Quintana from UTHealth Houston, and will investigate the efficacy and safety of hymecromone.

Data highlights:

The publication, entitled "Oral hymecromone decreases hyaluronan in human subjects," reports on Halo's phase I clinical study of its lead compound, hymecromone. The study enrolled 12 healthy volunteers for a total of 26 enrollments across three doses of hymecromone over the course of four days. No serious adverse events were reported, and hymecromone was well tolerated across all dose levels. A significant reduction in hyaluronan levels in the lungs of all participants was also observed, decreasing by an average of 25 percent. High levels of hyaluronan, an ECM glycosaminoglycan, are associated with lung injury and disease.

About Halo Biosciences

Halo Biosciences is a clinical stage biopharmaceutical company editing the extracellular matrix (ECM) to transform the treatment of diseases characterized by inflammation and fibrosis. The company is building a differentiated pipeline based on unique insights into ECM biology and its role in the progression of multiple diseases. Halo Biosciences is headquartered in Palo Alto, CA. For more information visit www.halobiosciences.com.

Contact:

contactus@halobiosciences.com.